You are here
AusPAR: Bevacizumab
Related information
How to access a pdf or Word document
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.
Australian Public Assessment Report
3 December 2020
| AusPAR | |
|---|---|
| Active Ingredient | Bevacizumab
|
| Product Name | Mvasi
|
| Sponsor | Amgen Australia Pty Ltd
|
| Submission Number | PM-2017-04616-1-4
|
| Submission Type | New biosimilar medicine
|
| Decision | Approved
|
| AusPAR Date | 23 November 2020
|
| Publication Date | 3 December 2020 |